{"entity":{"type":"insider","cik":"0001555953","url":"/insider/0001555953","json_url":"/insider/0001555953.json","name":"5AM Partners III, LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":18,"n_filings":8,"first":"2013-11-20","last":"2019-07-01","span_basis":"filed_date"},"name_variants":[{"name":"5AM Partners III, LLC","source":"filing","n_filings":8,"first_seen":"2013-11-20","last_seen":"2019-07-01"}],"transactions":[{"id":7912794,"accession":"0001104659-19-038785","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-19-038785","line_url":"/filing/0001104659-19-038785","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"ARVINAS, INC.","issuer_ticker":"ARVN","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"Schwab Andrew J.; 5AM Co-Investors III, L.P.; DIEKMAN JOHN D; 5AM Partners III, LLC; ROCKLAGE SCOTT M; 5AM VENTURES III, L.P.","owner_display_name":"Schwab Andrew J.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":360000.0,"shares_display":"360,000","price_per_share":22.02,"price_display":"22.02","price_state":"stated","total_value":7927200.0,"total_display":"7,927,200.00","total_whole":"7,927,200","shares_owned_after":3537261.0,"shares_owned_after_display":"3,537,261","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-28","filed_date":"2019-07-01","scope":"insider","n_lines":2},{"id":7912788,"accession":"0001104659-19-038785","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-19-038785","line_url":"/filing/0001104659-19-038785","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"ARVINAS, INC.","issuer_ticker":"ARVN","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"Schwab Andrew J.; 5AM Co-Investors III, L.P.; DIEKMAN JOHN D; 5AM Partners III, LLC; ROCKLAGE SCOTT M; 5AM VENTURES III, L.P.","owner_display_name":"Schwab Andrew J.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":450000.0,"shares_display":"450,000","price_per_share":21.75,"price_display":"21.75","price_state":"stated","total_value":9787500.0,"total_display":"9,787,500.00","total_whole":"9,787,500","shares_owned_after":3888216.0,"shares_owned_after_display":"3,888,216","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-27","filed_date":"2019-07-01","scope":"insider","n_lines":2},{"id":8667415,"accession":"0001104659-19-034661","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-19-034661","line_url":"/filing/0001104659-19-034661","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"ARVINAS, INC.","issuer_ticker":"ARVN","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM VENTURES III, L.P.; Schwab Andrew J.; 5AM Co-Investors III, L.P.; ROCKLAGE SCOTT M; 5AM Partners III, LLC; DIEKMAN JOHN D","owner_display_name":"5AM VENTURES III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":190000.0,"shares_display":"190,000","price_per_share":19.65,"price_display":"19.65","price_state":"stated","total_value":3733500.0,"total_display":"3,733,500.00","total_whole":"3,733,500","shares_owned_after":4326910.0,"shares_owned_after_display":"4,326,910","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-07","filed_date":"2019-06-11","scope":"insider","n_lines":2},{"id":8237417,"accession":"0001104659-19-019024","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-19-019024","line_url":"/filing/0001104659-19-019024","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"ARVINAS, INC.","issuer_ticker":"ARVN","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Co-Investors III, L.P.; ROCKLAGE SCOTT M; DIEKMAN JOHN D; 5AM VENTURES III, L.P.; 5AM Partners III, LLC; Schwab Andrew J.","owner_display_name":"5AM Co-Investors III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":361129.0,"shares_display":"361,129","price_per_share":14.1575,"price_display":"14.16","price_state":"stated","total_value":5112683.8175,"total_display":"5,112,683.82","total_whole":"5,112,684","shares_owned_after":4512136.0,"shares_owned_after_display":"4,512,136","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-28","filed_date":"2019-04-01","scope":"insider","n_lines":2},{"id":4161162,"accession":"0001209191-17-028279","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-028279","line_url":"/filing/0001209191-17-028279","is_derivative":false,"issuer_cik":"0001219014","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001219014","owner_cik":null,"owner_name":"5AM Partners III, LLC; ROCKLAGE SCOTT M; DIEKMAN JOHN D; Schwab Andrew J.; 5AM VENTURES III, L.P.; 5AM Co-Investors III, L.P.","owner_display_name":"5AM Partners III, LLC","owner_url":null,"role":"Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":172413.0,"shares_display":"172,413","price_per_share":14.5,"price_display":"14.50","price_state":"stated","total_value":2499988.5,"total_display":"2,499,988.50","total_whole":"2,499,989","shares_owned_after":2500113.0,"shares_owned_after_display":"2,500,113","ownership_form":"I","is_10b5_1":null,"transaction_date":"2017-04-24","filed_date":"2017-04-26","scope":"insider","n_lines":2},{"id":3293809,"accession":"0001209191-16-133847","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-16-133847","line_url":"/filing/0001209191-16-133847","is_derivative":false,"issuer_cik":"0001555953","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001555953","owner_cik":"0001555953","owner_name":"5AM Partners III, LLC","owner_display_name":"5AM Partners III, LLC","owner_url":"/insider/0001555953","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":70000.0,"shares_display":"70,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":1050000.0,"total_display":"1,050,000.00","total_whole":"1,050,000","shares_owned_after":2332031.0,"shares_owned_after_display":"2,332,031","ownership_form":"I","is_10b5_1":null,"transaction_date":"2016-07-25","filed_date":"2016-07-25","scope":"insider","n_lines":2},{"id":8949725,"accession":"0001144204-15-006678","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-15-006678","line_url":"/filing/0001144204-15-006678","is_derivative":false,"issuer_cik":"0001135906","issuer_name":"EPIRUS Biopharmaceuticals, Inc.","issuer_ticker":"EPRS","issuer_name_source":null,"issuer_url":"/issuer/0001135906","owner_cik":null,"owner_name":"5AM VENTURES III, L.P.; 5AM Co-Investors III, L.P.; Schwab Andrew J.; DIEKMAN JOHN D; 5AM Partners III, LLC","owner_display_name":"5AM VENTURES III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":400000.0,"shares_display":"400,000","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":2000000.0,"total_display":"2,000,000.00","total_whole":"2,000,000","shares_owned_after":2549211.0,"shares_owned_after_display":"2,549,211","ownership_form":"I","is_10b5_1":null,"transaction_date":"2015-02-04","filed_date":"2015-02-06","scope":"insider","n_lines":2},{"id":6378950,"accession":"0001144204-14-073463","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-14-073463","line_url":"/filing/0001144204-14-073463","is_derivative":false,"issuer_cik":"0001416792","issuer_name":"Relypsa Inc","issuer_ticker":"RLYP","issuer_name_source":null,"issuer_url":"/issuer/0001416792","owner_cik":null,"owner_name":"5AM Co-Investors III, L.P.; 5AM VENTURES III, L.P.; 5AM Partners III, LLC","owner_display_name":"5AM Co-Investors III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":589637.0,"shares_display":"589,637","price_per_share":30.04,"price_display":"30.04","price_state":"stated","total_value":17712695.48,"total_display":"17,712,695.48","total_whole":"17,712,695","shares_owned_after":1843243.0,"shares_owned_after_display":"1,843,243","ownership_form":"I","is_10b5_1":null,"transaction_date":"2014-12-09","filed_date":"2014-12-11","scope":"insider","n_lines":2},{"id":4341421,"accession":"0001181431-13-060006","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001181431-13-060006","line_url":"/filing/0001181431-13-060006","is_derivative":false,"issuer_cik":"0001416792","issuer_name":"Relypsa Inc","issuer_ticker":"RLYP","issuer_name_source":null,"issuer_url":"/issuer/0001416792","owner_cik":null,"owner_name":"5AM Co-Investors III, L.P.; 5AM VENTURES III, L.P.; 5AM Partners III, LLC","owner_display_name":"5AM Co-Investors III, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":372692.0,"shares_display":"372,692","price_per_share":11.0,"price_display":"11.00","price_state":"stated","total_value":4099612.0,"total_display":"4,099,612.00","total_whole":"4,099,612","shares_owned_after":2418066.0,"shares_owned_after_display":"2,418,066","ownership_form":"I","is_10b5_1":null,"transaction_date":"2013-11-20","filed_date":"2013-11-20","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":2,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":2,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":2},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001655759","name":"ARVINAS, INC.","url":"/issuer/0001655759","role":"Ten percent owner","n_filings":3,"first_seen":"2019-04-01","last_seen":"2019-07-01"},{"type":"issuer","type_label":"ISSUER","cik":"0001628738","name":"Audentes Therapeutics, Inc.","url":"/issuer/0001628738","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2016-07-25","last_seen":"2017-04-26"},{"type":"issuer","type_label":"ISSUER","cik":"0001135906","name":"EPIRUS Biopharmaceuticals, Inc.","url":"/issuer/0001135906","role":"Ten percent owner","n_filings":1,"first_seen":"2015-02-06","last_seen":"2015-02-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001416792","name":"Relypsa Inc","url":"/issuer/0001416792","role":"Ten percent owner","n_filings":2,"first_seen":"2013-11-20","last_seen":"2014-12-11"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001555953","retrieved_at":"2026-08-24T05:04:02+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}